Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on hard-to-treat cancers and viruses. Its lead candidate, Annamycin (naxtarubicin), is a next-generation anthracycline currently in a pivotal Phase 3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (AML). The company also develops WP1066 portfolio compounds targeting p-STAT3 and WP1122 portfolio glycolysis inhibitors. All three core technologies are substantially based on discoveries licensed from MD Anderson Cancer Center.
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-18 | 2025-12-31 | 0001437749-26-008841 | EDGAR | 92K words |
| 2025-03-21 | 2024-12-31 | 0001437749-25-008751 | EDGAR | 79K words |
| 2024-03-22 | 2023-12-31 | 0001437749-24-009044 | EDGAR | 79K words |
| 2023-03-22 | 2022-12-31 | 0001437749-23-007537 | EDGAR | 76K words |
| 2022-03-24 | 2021-12-31 | 0001437749-22-007103 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001437749-21-006940 | EDGAR | — |
| 2020-03-19 | 2019-12-31 | 0001659617-20-000066 | EDGAR | — |
| 2019-02-21 | 2018-12-31 | 0001659617-19-000018 | EDGAR | — |
| 2018-03-28 | 2017-12-31 | 0001659617-18-000027 | EDGAR | — |
| 2017-04-03 | 2016-12-31 | 0001144204-17-018352 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001437749-26-027688 | EDGAR | 20K words |
| 2025-11-13 | 2025-09-30 | 0001437749-25-034839 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001437749-25-026225 | EDGAR | 21K words |
| 2025-05-13 | 2025-03-31 | 0001437749-25-016466 | EDGAR | 15K words |
| 2024-11-08 | 2024-09-30 | 0001437749-24-034236 | EDGAR | 19K words |
| 2024-08-13 | 2024-06-30 | 0001437749-24-026367 | EDGAR | 14K words |
| 2024-05-10 | 2024-03-31 | 0001437749-24-016031 | EDGAR | 12K words |
| 2023-11-13 | 2023-09-30 | 0001437749-23-031391 | EDGAR | 19K words |
| 2023-08-10 | 2023-06-30 | 0001437749-23-023021 | EDGAR | 17K words |
| 2023-05-10 | 2023-03-31 | 0001437749-23-013582 | EDGAR | 14K words |
| 2022-11-10 | 2022-09-30 | 0001437749-22-026888 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001437749-22-020389 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-29 | 0001437749-26-031419 | EDGAR | — |
| 2026-09-28 | 0001437749-26-031280 | EDGAR | 1K words |
| 2026-09-25 | 0001437749-26-031199 | EDGAR | 1K words |
| 2026-09-23 | 0001437749-26-031005 | EDGAR | 1K words |
| 2026-09-18 | 0001437749-26-030757 | EDGAR | 1K words |
| 2026-09-14 | 0001437749-26-030315 | EDGAR | 1K words |
| 2026-08-31 | 0001437749-26-029336 | EDGAR | 0K words |
| 2026-08-14 | 0001437749-26-027835 | EDGAR | 3K words |
| 2026-08-03 | 0001437749-26-025474 | EDGAR | 20K words |
| 2026-07-31 | 0001437749-26-025167 | EDGAR | 1K words |
506 total filings indexed. 474 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001659617 |
| Ticker | MBRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.moleculin.com |
| Listed | 2016-06-02 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/MBRX (~200 tokens, structured JSON with cryptographic provenance)